PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-7.91%
Revenue decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
-9.79%
Cost reduction while Medical - Pharmaceuticals median is 1.22%. Seth Klarman would investigate competitive advantage potential.
0.58%
Growth of 0.58% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
9.21%
Margin change of 9.21% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.62%
Other expenses change of 23.62% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
1.39%
Operating expenses growth 1.1-1.25x Medical - Pharmaceuticals median of 1.12%. John Neff would investigate control.
-8.15%
Total costs reduction while Medical - Pharmaceuticals median is 1.67%. Seth Klarman would investigate advantages.
16.67%
Interest expense change of 16.67% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
23.01%
D&A change of 23.01% versus flat Medical - Pharmaceuticals D&A. Walter Schloss would verify adequacy.
0.43%
EBITDA change of 0.43% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
9.05%
Margin change of 9.05% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-2.15%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
6.24%
Margin change of 6.24% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
35.35%
Other expenses change of 35.35% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
0.38%
Income change of 0.38% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
9.00%
Margin change of 9.00% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
4.49%
Tax expense change of 4.49% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
-2.62%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
5.74%
Margin change of 5.74% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-2.63%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-2.63%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.